Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

Viewpoints_Maria Belvisi_Dr. Sarah Doffman_Dr. Janet Franklin
ATS 2024: Maria Belvisi, Sarah Doffman, and Janet Franklin from AstraZeneca & Amgen in a Stimulating Conversation with PharmaShots
Shots:  Jointly developed by AstraZeneca & Amgen, AZD8630/AMG targets Thymic stromal lymphopoietin (TSLP), an epithelial cytokine involved in Chronic Inflammatory Disorders  Recently, AstraZeneca and Amgen released the P-I data evaluating AZD8630/AMG104 on three doses vs. placebo for 28 days. The data demonstrated linear PK at all three doses  Today, at PharmaShots we have Prof. Maria…
October 7, 2024
Viewpoints_Robert Fogel_Dave Singh
AstraZeneca at ATS’24: Robert Fogel & Dave Singh in a Stimulating Conversation with PharmaShots
Shots:  Cardiopulmonary events associated with COPD are responsible for an increasing mortality rate in COPD patients. ETHOS trial, a posthoc analysis navigates BGF’s impact on a wide range of cardiopulmonary outcomes beyond COPD exacerbations  The post-hoc analysis reveals that AstraZeneca’s Breztri led to a 20% reduction in the risk of severe cardiopulmonary events. AstraZeneca is currently…
September 30, 2024
Viewpoints_Sofie Berg
Unlocking Approval: Sofie Berg from AbbVie in an Illuminating Dialogue Exchange with PharmaShots
Shots:  Recently, the European Commission approved AbbVie’s Skyrizi for the treatment of adults with moderate to severe active Ulcerative Colitis  The approval was based on positive data from the P-III INSPIRE induction trial and COMMAND maintenance study   Today, at PharmaShots we have Sofie Berg, the therapeutic area head of international immunology, International Medical Affairs, at…
September 23, 2024
Viewpoints_Jacqueline Nielsen_Tahi Ahmadi
Unlocking Approval: Jacqueline Nielsen from AbbVie & Tahi Ahmadi from Genmab in a Riveting Conversation with PharmaShots
Shots:  Recently, the EMA’s CHMP adopted a positive opinion by recommending conditional marketing authorization for AbbVie and Genmab’s Tepkinly for the treatment of R/R Follicular Lymphoma  Today at PharmaShots, we have Jacqueline Nielsen, Head of Hematologic Oncology Affairs at AbbVie, and Tahi Ahmadi, EVP and CMO at Genmab, shedding light on this conditional marketing authorization…
September 18, 2024
Viewpoints_Ahsan Arozullah
Astellas at ASCO 2024: Ahsan Arozullah in an Illuminating Dialogue Exchange with PharmaShots
Shots:  At ASCO 2024, Astellas Pharma presented 16 abstracts across several types of cancers with unmet medical needs  Today at PharmaShots, we have Ahsan Arozullah Sr. VP, Head of Oncology Development, shedding light on the advancement Astellas’ oncology portfolio for urothelial carcinoma, gastric cancer, and prostate cancer  Ahsan talks about the presented results from studies…
September 16, 2024
Viewpoints_Christophe Piketty
Fingers Crossed: Christophe Piketty from Galderma in a Stimulating Conversation with PharmaShots
Shots:  Atopic dermatitis remains one of the most common inflammatory skin diseases, affecting more than 230M people across the globe. Characterized by frequent itching and recurrent skin lesions, atopic dermatitis is a chronic condition  Recently the Lancet published data from Galderma’s P-III trial, ARCADIA 1 and ARCADIA 2, demonstrating the potential of nemolizumab to improve skin…
September 11, 2024
Viewpoints_Piotr Trzonkowski
Enhancing Care: Piotr Trzonkowski from PolTREG in an Interesting Dialogue Exchange with PharmaShots
Shots:   Recently, PolTREG announced positive long-term follow-up data for PTG-007 from the P-I/II studies for early-onset type 1 diabetes  PolTREG develops therapies using T-regulatory cells for autoimmune diseases. With the positive results, PolTREG has met EMA’s requirement to confirm the safety of Treg therapies at least five years after the administration  Today, at PharmaShots, we…
September 4, 2024
Viewpoints_Kasper Roet 
Advancing Neurodegenerative Care: Kasper Roet from QurAlis Corporation in a Stimulating Conversation with PharmaShots
Shots:  Recently, QurAlis signed an exclusive license agreement with Lilly for QRL-204 for patients with ALS and FTD  Under the terms of the agreement, QurAlis granted Lilly an exclusive worldwide license to develop and commercialize QRL-204 and other UNC13A targeting compounds.  QurAlis received an up front payment of $45M plus an additional equity investment. The company is…
September 2, 2024
Load more